Navigation Links
Sanford-Burnham scientists unravel cancer drug's secret to resistance
Date:3/19/2012

LA JOLLA, Calif., March 19, 2012 Drug resistance is a serious problem for cancer patientsover time, a therapy that was once providing some benefit simply stops working. Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) recently discovered how cancer cells develop resistance to a drug called MLN4924. This experimental therapy is currently being tested in a number of Phase I and Phase I/II clinical trials to determine its efficacy against several different types of cancer, including multiple myeloma, leukemia, and lymphoma.

Published online March 19 by Cell Reports, the study shows that MLN4924-resistant cancer cells escape death because they have a simple mutation in the drug's targetNEDD8-activating enzymethat prevents the drug from binding. In unraveling this mechanism, the researchers also developed a relatively quick, low-cost laboratory method that can be used to personalize cancer therapies by predicting how cancer patients will respond to this or other drugsall before a person starts taking it.

"Due to genetic variability, some tumors might be more prone to developing resistance to treatment than others. Pinpointing the right treatment for an individual can be a frustrating and costly trial-and-error process. The method we developed in this study to determine the mechanism of resistance for one anti-cancer drug gives us a jumpstart on knowing if this resistance mechanism will hold true for other drugspotentially saving time and money," said Matthew Petroski, Ph.D., assistant professor in Sanford-Burnham's National Cancer Institute-designated Cancer Center and senior author of the study.

MLN4924: Promising anti-cancer drug

MLN4924 kills most cancer cells by binding and inactivating the NEDD8-activating enzyme. NEDD8 and the enzymes that control it are part of the ubiquitin proteasome system (so-named because it's ubiquitous, found in every cell in the body).

This comp
'/>"/>

Contact: Heather Buschman, Ph.D.
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Sanford-Burnham research advances to patient studies at TRI
2. Sanford-Burnham and Florida Hospital review obesity research progress with Takeda Pharmaceutical
3. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
4. Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
5. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
6. Dr. Kristiina Vuori Promoted to President of Sanford-Burnham Medical Research Institute
7. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
8. Scientists develop a software tool for estimating heart disease risk
9. UCLA scientists uncover mechanism for melanoma drug resistance
10. No workout? No worries: Scientists prevent muscle loss in mice, despite disease and inactivity
11. New test can better predict successful IVF embryos, scientists say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sanford-Burnham scientists unravel cancer drug's secret to resistance
(Date:7/24/2014)... overweight and obese preschoolers works better when treatment targets ... child is targeted, according to research published this week ... at Buffalo and Women and Children,s Hospital of Buffalo., ... and had one parent who participated in the study ... mass index (BMI) measurements, calculated based on height and ...
(Date:7/24/2014)... 24, 2014 News Facts , ... has achieved certification for compliance with Department of ... by the DoD Information Assurance Certification and Accreditation ... identified within the DoD as the Enterprise Clinical ... designation from the U.S. Army Medical Materiel Agency. ...
(Date:7/24/2014)... material like a medical device or surgical implant is ... According to Northwestern University,s Guillermo Ameer, most of the ... device,s function. , "You will always get an inflammatory ... engineering in Northwestern,s McCormick School of Engineering and Applied ... of Medicine. "A problem with commonly used plastic materials, ...
(Date:7/24/2014)... 2014 A new study led by the Translational ... among bacteria, viruses and the immune system during HIV ... their potential to infect others based on their ... of virus in their semen despite having low levels ... levels of the virus can be found in different ...
(Date:7/24/2014)... 24, 2014 Horizon BCBSNJ’s second annual ... lucky family a rent-free week in a beautiful Lavallette ... 2014. Don’t miss your chance to win a week’s ... to all New Jersey residents, 25 or older.* Residents ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Antioxidant biomaterial promotes healing 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... plague is significantly slowed when it can't make use of ... in St. Louis report in this week's issue of Science. ... plague, which kills in three to four days and potentially ... causes plague, Yersinia pestis, is vulnerable to antibiotics, but by ...
... dehydrogenase (ADH) is one of the major enzymes involved ... at two loci, ADH1B and ADH1C.// ,The ... linked with protection from alcohol dependence, a new study ... ADH1B*3 allele and alcohol-related disorders among Afro-Trinidadians. Findings indicate ...
... inflammatory disorder that causes degeneration of the nerves in ... including muscle// weakness and pain. ,Most ... remission, leading to the suggestion that there are regulatory ... model of MS (known as EAE), researchers from the ...
... Corps is to get a mega centre with multi-specialities, ... for this here Thursday.// ,The facility will ... (Research & Referral) and will be known as Army ... under one roof facilities for training dental officers, specialists ...
... (Zyban) and nortriptyline double a person’s chances //of giving ... reuptake inhibitors (SSRIs) such as fluoxetine (Prozac) are not ... to help people quit smoking, not everyone is helped ... alternative is to use antidepressants. The rationale for this ...
... India - Dr. Avul Pakir Jainulabdeen Abdul Kalam released ... Shri - on the eve of the Republic Day. ... Committee’ makes the final recommendations on awardees after receiving ... central ministries and departments and institutions of excellence, and ...
Cached Medicine News:Health News:Disabling Key Protein may Give Physicians Time to Treat Pneumonic Plague 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 3Health News:Majority of Padma Awards Go to Doctors from Delhi 2
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Alimera Sciences To Release Second Quarter 2014 Results 2
... in LDL-C when Treated with 300 mg/week ISIS 301012 ... for 13 Weeks, - Study Presented in Poster Session Today at DALM Symposium in New York ... City, - Isis Will Host a Conference ... at http://www.isispharm.com , ...
... today,announced that the company has been awarded a ... and Technology (NIST) to develop a Sensor,System on ... markers in,a single assay. Successful development of ... of multifactorial conditions such as autoimmune disease and,allergy, ...
Cached Medicine Technology:Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 6Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 2Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 3Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 4
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein G - 50 OD...
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: